Immunological effects and membrane interactions of chitosan nanoparticles

Molecular Pharmaceutics

Volumn 6, Issue 2, 2009, Pages 345-352

  Pattani, Aditya ^a,b   Patravale, Vandana B ^b   Panicker, Lata ^c   Potdar, Pravin D ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^c BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Chitosan nanoparticles; Dipalmitoyl phosphatidylcholine membrane interactions; Immunomodulation; Interleukin 6; Lymphocyte; Nitric oxide

Indexed keywords

CHITOSAN; INTERLEUKIN 6; NANOPARTICLE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; WOUND HEALING;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; BIOCOMPATIBLE MATERIALS; CELL MEMBRANE; CELLS, CULTURED; CHITOSAN; HUMANS; INTERLEUKIN-6; LYMPHOCYTES; NANOPARTICLES; NITRIC OXIDE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; WOUND HEALING;

EID: 64649086749     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900004b     Document Type: Article

References (32)

1. Kreuter, J. Nanoparticle-based dmg delivery systems. J. Controlled Release 1991, 16, 169-176.
2. Couvreur, P.; Fattal, E.; Andremont, A. Liposomes and Nano- particles in the Treatment of Intracellular Bacterial Infections. Pharm. Res. 1991, 8, 1079-1086.
3. Lecaroz, C.; Gamazo, C.; Blanco-Prieto, M. J. Nanocarriers with gentamicin to treat intracellular pathogens. J. Nanosci. Nanotech- nol. 2006, 6, 3296-3302.
4. Mottram, P. L.; Leong, D.; Crimeen-Irwin, B.; Gloster, S.; Xiang, 5. D.; Meanger, J.; Ghildyal, R.; Vardaxis, N.; Plebanski, M. Type 1 and 2 immunity following vaccination is influenced by nano- particle size: Formulation of a model vaccine for respiratory syncytial virus. Mol. Pharmaceutics 2007, 4, 73-84.
5. Storni, T.; Kundig, T. M.; Senti, G.; Johansen, P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Delivery Rev. 2005, 57, 333-355.
6. Gomez, S.; Gamazo, C.; Roman, B. S.; Vauthier, C.; Ferrer, M.; Irache, J. M. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J. Nanosci. Nanotechnol. 2006, 6, 3283-3289.
7. Khatri, K.; Goyal, A. K.; Gupta, P. N.; Mishra, N.; Vyas, S. P. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int. J. Pharm. 2008, 554, 235-241.
8. Borges, O.; Tavares, J.; de Sousa, A.; Borchard, G.; Junginger, H. E.; Cordeiro-da-Silva, A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur. J. Pharm. Sci. 2007, 32, 278-290.
9. Yang, Y.; Chen, J.; Li, H.; Wang, Y.; Xie, Z.; Wu, M.; Zhang, H.; Zhao, Z.; Chen, Q.; Fu, M.; Wu, K.; Chi, C.; Wang, H.; Gao, R. Porcine interleukin-2 gene encapsulated in chitosan nanopar- ticles enhances immune response of mice to piglet paratyphoid vaccine. Comp. Immunol. Microbiol. Infect. Dis. 2007, 30, 19-32.
10. Hong, H.; Jin, S.; Park, J.; Ahn, W. S.; Kim, C. Accelerated wound healing by smad3 antisense ohgonucleotides-impregnated chitosan/ alginate polyelectrolyte complex. Biomaterials 2008, 29, 4831-4837.
11. Ueno, H.; Mori, T.; Fujinaga, T. Topical formulations and wound healing applications of chitosan. Adv. Drug Delivery Rev. 2001, 52, 105-115.
12. Kim, I. Y.; Yoo, M. K.; Seo, J. H.; Park, S. S.; Na, H. S.; Lee, H. C.; Kim, S. K.; Cho, C. S. Evaluation ofsemi-interpenetrating polymer networks composed of chitosan and poloxamer for wound dressing application. Int. J. Pharm. 2007, 341, 35-43.
13. Legrand-Poels, S.; Schoonbroodt, S.; Piette, J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem. J. 2000, 549, 765-773.
14. Govindarajan, R.; Vijaykumar, M.; Rawat, A. K. S.; Mehrotra, S. Free Radical Scavenging Potential of Picrorhiza kurrooa Royle ex Benth. Indian J. Exp. Biol. 2003, 41, 875-879.
15. Ventura, C. A.; Tommasini, S.; Crupi, E.; Giannone, I.; Cardile, V.; Musumeci, T.; Puglisi, G. Chitosan microspheres for intra- pulmonary administration of moxifloxacin: Interaction with biomembrane models and in vitro permeation studies. Eur. J. Pharm Rionharm. 2008, 68, 235-244.
16. Huang, C.; Li, S. Calorimetric and molecular mechanics studies of the thermotropic phase behavior of membrane phospholipids. Biochim. Biophys. Acta 1999, 1422, 273-307.
17. Koynova, R.; Caffrey, M. Phases and phase transitions of the phosphatidylcholines. Biochim. Biophy. Acta 1998, 1376, 91-145.
18. Bertoluzza, A.; Bonora, S.; Fini, G.; Francioso, O.; Morelli, M. A. Interaction of bipyridilium herbicides with model membranes. Chem. Phys. Lipids 1995, 75, 137-143.
19. Biltonen, R. L.; Lichtenberg, D. The use of differential scanning calorimetry as a tool to characterize liposome preparations. Chem. Phys. Lipids 1993, 64, 129-142.
20. Scholer, N.; Zimmermann, E.; Katzfey, U.; Hahn, H.; Muller, R. H.; Liesenfeld, O. Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J. Microencapsulation 2000, 17, 639-650.
21. Park, E.; Yi, J.; Chung, K.; Ryu, D.; Choi, J.; Park, K. Oxidative stress and apoptosis induced by titanium dioxide nanoparticles in cultured BEAS-2B cells. Toxicol. Lett. 2008, 180, 222-229.
22. Grandjean-Laquerriere, A.; Laquerriere, P.; Guenounou, M.; Laurent-Maquin, D.; Phillips, T. M. Importance of the surface area ratio on cytokines production by human monocytes in vitro induced by various hydroxyapatite particles. Biomaterials 2005, 26, 2361-2369.
23. Laquerriere, P.; Grandjean-Laquerriere, A.; Jallot, E.; Balossier, G.; Frayssinet, P.; Guenounou, M. Importance of hydroxyapatite particles characteristics on cytokines production by human mono- cytes in vitro. Biomaterials 2003, 24, 2739-2747.
24. Chellat, F.; Grandjean-Laquerriere, A.; Naour, R. L.; Fernandes, J.; Yahia, L.; Guenounou, M.; Laurent-Maquin, D. Metallopro- teinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials 2005, 26, 961-970.
25. Luzardo-Alvarez, A.; Blarer, N.; Peter, K.; Romero, J. F.; Reymond, C.; Corradin, G.; Gander, B. Biodegradable micro- spheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J. Controlled Release 2005, 109, 62-76.
26. Fecho, K.; Maslonek, K.; Coussons-Read, M.; Dykstra, L.; Lysle, D. Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J. Immunol. 1994, 152, 5845-5852.
27. *0201- restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 2004, 22, 1609-1615.
28. Gyan, B.; Troyeblomberg, M.; Perlmann, P.; Bjorkman, A. Human Monocytes Cultured with and without Interferon-Gamma Inhibit Plasmodium-Falciparum Parasite Growth In-Vitro Via Secretion of Reactive Nitrogen Intermediates. Parasite Immunol. 1994, 16, 371-375.
29. Mellouk, S.; Hoffman, S. L.; Liu, Z. Z.; Delavega, P.; Billiar, T. R.; Nussler, A. K. Nitric Oxide-Mediated Antiplasmodial Activity in Human and Murine Hepatocytes Induced by Gamma- Interferon and the Parasite itself - Enhancement by Exogenous Tetrahydrobiopterin. Infect. Immun. 1994, 62, 4043-4046.
30. Chan, E. D.; Chan, J.; Schluger, N. W. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am. J. Res. Cell Mol. Biol. 2001, 25, 606-612.
31. Yamasaki, K.; Edington, H. D. J.; McClosky, C.; Tzeng, E.; Lizonova, A.; Kovesdi, I.; Steed, D. L.; Billiar, T. R. Reversal of impaired wound repair in iNOS-deficient mice by topical aden- oviral-mediated iNOS gene transfer. J. Clin. Invest. 1998, 101, 967-971.
32. Cole-King, A.; Harding, K. G. Psychological factors and delayed healing in chronic wounds. Psychosom. Med. 2001, 63, 216-220.